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ABSTRACT 
A prospective open-label trial was performed to compare the efficacy of dolasetron with at of ondansetron or 
granisetron (standard therapy) for prevention of nausea nd vomiting associated with high-dose chemotherapy with 
or without otal body irradiation followed by hematopoietic stem cell transplantation (HSCT). In a university teach- 
ing hospital setting, 62 patients were randomized to receive either dolasetron 100 mg daily or standard oses of 
ondansetron or granisetron. In addition to objective data such as number of episodes of emesis and quantity of res- 
cue antiemetics required, 100mm visual analogue scales were used to rate nausea, appetite, and changes in taste. A 
post-hoe subgroup analysis was performed between groups of patients that were matched for c nditioning regi- 
mens. Sixty-five percent of the dolasetron-treated patients and 87% of patients in the standard therapy group 
achieved a major or complete response (P < .05) based on emetic episodes and nausea score. Patients in the standard 
therapy group sed fewer rescue antiemetics and also rated more favorably on selected questions of the visual ana- 
logue scale. No differences in safety parameters or adverse ffects were reported. At doses prescribed in this study, 
dolasetron was less effective than granisetron or ondansetron i preventing nausea nd vomiting associated with 
high-dose chemotherapy/total body irradiation followed by HSCT. 
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INTRODUCTION 
Three 5-hydroxytry-ptamine-3 (5-HT3) receptor antago- 
nists, dolasetron (injectable), ondansetron, and granisetron, 
are approved in the United States for the prevention of nau- 
sea and vomiting associated with initial and repeat courses 
of emetogenic cancer chemotherapy, including high-dose 
cisplatin [1-4]. Oral dolasetron is indicated for the preven- 
tion of nausea and vomiting associated with moderately 
emetogenic ancer chemotherapy, including initial and 
repeat courses [5]. These products may be synergistic with 
benzodiazepines, phenothiazines, and dexamethasone i  the 
control of nausea nd emesis [6,7]. Despite these measures, 
the majority of hematopoietic stem cell transplantation 
(HSCT) patients receiving high-dose chemotherapy con- 
tinue to experience nausea nd emesis [8,9]. 
Dolasetron has been studied alone in bone marrow 
transplantation (BMT) and has been compared with both 
granisetron and ondansetron i  high-dose chemotherapy 
regimens [10-12]. Granisetron and ondansetron have 
demonstrated similar efficacy in a previously published 
study of high-dose chemotherapy followed by BMT [13]. 
It is generally accepted that ondansetron, granisetron, and 
dolasetron are equivalent in efficacy and safety when used 
to control chemotherapy-induced nausea and vomiting at 
approved oses [7,14]. However, there has been no pub- 
lished comparison of dolasetron to either ondansetron or 
granisetron in h igh-dose chemotherapy fol lowed by 
HSCT. For this reason, this investigation was designed to 
compare the safety and efficacy of dolasetron versus ondan- 
setron or granisetron in patients undergoing high-dose 
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Table I .  Conditioning and Antiemetic Regimens Used* 
Dolasetron 
Conditioning Therapy Group, n 
Standard 
Group, n 
BEAM 2 3 
Bu-Thio-TBI I 3 
Bu-Hel-Thio 4 I 
TBI 1320-Etop60 0 2 
Bu 16-Cy 120 2 3 
Bu 14-Cy150 I 0 
Bu 16-Cy200 0 I 
CBV I 2 
Cy-Thio-Carbo 5 6 
BCNU-Etop-Cis I 0 
Cy 100-Etop60-TBI 1200 2 0 
Cy 120-TBI 1200 I 0 I 0 
Cy 120-TBI 1400 2 0 
*BEAM indicates carmustine, toposide, cytosine arabinoside, and 
melphalan; Bu, busulfan; Thio, thiotepa; TBI, total body irradiation; 
Mel, melphalan; Etop, etoposide; Cy, cyclophosphamide; CBV, 
cyclophosphamide, carmustine, and etoposide; Carbo, carboplatin; Cis, 
cisplatin. Units of measure for doses pecified inconditioning therapies 
are as follows: TBI, eGy; Etop, mg/kg; Bu, mg/kg; Cy, mg/kg. 
chemotherapy with or without total body irradiation fol- 
lowed by HSCT. 
PATIENTS AND METHODS 
At our institution, standard antiemetic regimens have 
been developed through prior experience and according to 
supporting literature for controlling nausea and vomiting 
associated with high-dose chemotherapy with HSCT 
(Table 1). Each conditioning regimen is associated with a 
standard antiemetic regimen containing ondansetron or 
granisetron. Both 5-HT 3 receptor antagonists are used 
rather than a single agent because at the time these regi- 
mens were developed, extended interval dosing with 
ondansetron had not been investigated. The following are 
the standard antiemetic regimens that accompany each of 
the conditioning regimens used in this study. For the regi- 
mens of 16 mg/kg busulfan (Bu)-120 mg/kg cyclophos- 
phamide (Cy); 14 mg/kg Bu-150 mg/kg Cy; 16 mg/kg 
Bu-200 mg/kg Cy; 120 mg/kg Cy-1200 cGy total body irra- 
diation (TBI); 120 mg/kg Cy-1400 cGy TBI; 1320 cGy 
TBI-60 mg/kg etoposide (Etop); and 100 mg/kg Cy-60 
mg/kg Etop-1200 cGy TBI, the following antiemetic ther- 
apy is given: 20 mg intravenous (IV) dexamethasone daily 
on days of TBI, etoposide, or cyclophosphamide; 10 mg IV 
ondansetron every 6 hours on days of cyclophosphamide; 
8 nag oral ondansetron every 6 hours on days of busulfan 
thera W or etoposide; and 8 mg oral ondansetron twice daily 
on days of TBI. The regimens Bn-thiotepa (Thio)-TBI and 
Bu- melphalan (Mel)-Thio are accompanied by the follow- 
ing: on days of thiotepa, melphalan, or TBI, 20 mg IV dex- 
amethasone daily; and on all days, 8 mg oral ondansetron 
every 6 hours. The regimen of Cy-carmustine (BCNU)- 
Etop (CBV) is accompanied by 20 mg IV dexamethasone, 
2 mg oral granisetron, and 1 mg oral lorazepam prior to 
chemotherapy each day. Patients receiving the BCNU- 
Etop-cytosine arabinoside-Mel (BEAM) regimen are treated 
with oral granisetron 1 mg every 12 hours and 20 mg IV 
dexamethasone daily for 6 days. Oral granisetron 2 mg 
before first dose of chemotherapy followed by 1 mg orally 
every 12 hours and 20 mg IV dexamethasone daily are given 
with 6000 mg/m z Cy-500 mg/m 2 Thio-800 mg/m 2 carbo- 
platin. Finally, the BCNU-Etop-cisplatin regimen is treated 
with 10 mg IV ondansetron and 1 mg oral lorazepam every 
6 hours, 20 mg IV dexamethasone daily, and prochlorper- 
azine 15 mg spansules every 8 hours for 6 days. Our intention 
was to maintain consistency within the antiemetic regimens 
and compare the effect of substituting dolasetron at 
prospectively defined doses in place of our standard 5-HT 3 
antagonists. In this study, dolasetron was used in place of 
either ondansetron or granisetron in the standard regimens 
and administered via the same route. 
Pat ients  
All patients invited to participate were adult inpatients 
(age, >_18 years) with Karnofsky performance criteria >70%. 
Subjects underwent conditioning regimens prior to antolo- 
gous, allogeneic, or syngeneic HSCT with high-dose chemo- 
therapy with or without radiation therapy. Female patients 
were required to be postmenopansal, surgically sterile, or on 
appropriate methods of contraception. Patients excluded 
from the study were those with uncontrolled (over the prior 
30 days) clinically significant confomlding medical conditions, 
including nausea, congestive heart failure, cardiomyopathy, 
greater than first degree heart block, preexisting complete 
bundle branch block, or requirement for antiarrhythmic med- 
ication. Other exclusion criteria for patients included were 
female patients who were pregnant, lactating, or had a posi- 
tive serum human chorionic gonadotropin; patients with 
known hypersensitivity o dolasetron; patients with nausea 
and vomiting due to organic etiologies uch as gastric outlet 
obstruction, increased intracranial pressure, or brain metas- 
tases; and patients concurrently using agents known to have 
significant antiemetic effects taken within 24 hours of begin- 
ning therapy (such as additional corticosteroids, benzodi- 
azepines, cannabinoids, antipsychoties, metoclopramide, and 
antihistamines). 
Study  Des ign  
After giving informed consent, patients received an initial 
evaluation by the investigators, who obtained complete med- 
ical histories including allergies, current medications, and 
medication histories. In this open-label study, subjects were 
randomized by the pharmacy through a random number table 
in blocks of 6 to either the dolasetron or standard therapy 
arm from November 1998 through August 1999. After ran- 
domization, patients received the antiemetic treatment tai- 
lored to their HSCT conditioning regimen as oudined previ- 
ously. Patients were assessed at baseline and every day after 
the initiation of conditioning through Day 0. Oral dolasetron 
was given at 100 mg per 24 hours as a single daily dose begin- 
ning 1 hour prior to chemotherapy. IV dolasetron was given 
at a dosage of 1.8 mg/kg (actual body weight) up to I00 mg 
every 24 hours as a single infusion over 15 minutes. It was 
planned a priori that the dosage would be increased to 100 mg 
every 12 hours if 3 of the first 5 patients using dolasetron had 
more than 1 emetic episode per day for more than 2 days. 
440 
Dolasetron Control of Nausea in HSCT 
Table  2. Patient Demographics* 
Dolasetron Standard Dolasetron Standard 
Intent ion-to-Treat Intention-to-Treat Conditioning-Matched Condit ioning-Matched 
Arm,  n Arm,  n Group, n Group, n 
No. of patients 31 31 22 22 
Median age, y 48 46 46.5 42.5 
Sex, M/F 16/15 19/12 | I / I  I 14/8 
Alcohol user 
None 9 9 4 7 
Occasional/moderate 20 16 16 13 
Heavy I 5 I I 
Prior chemotherapy (%) 29 (93.5) 30 (96.8) 21 21 
Prior XRT  (%) 9 (29.0) 8 (25.8) 7 4 
Auto/al lo 15/16 16/15 I I / I I 12/I 0 
Mean -+ SD performance status, % 98.5 + 3.6 98.5 + 4.4 99 s 3 99.5 s 2.2 
*XRT indicates external beam radiation therapy; auto, autologous; allo, allogeneic. 
tFor alcohol use, heavy was defined as daily use or weekly binge drinking; moderate, several drinks per week; occasional, 1 drink per week or fewer. 
Eva luat ion  o f  Response  
A 100-mru visual analogue scale (VAS) was used to assess 
subjects' feelings of nausea, changes in taste, and nutritional 
requirements. The VAS included the questions "Do you have 
nausea?"; "Do you vomit?"; "Have you had any changes in 
taste?"; "How much of an appetite do you have?"; and "Is the 
amount you eat sufficient for your needs?" Subjects were asked 
to refer to the last 24-hour time period when answering each 
question. Subjects made a slash mark on the corresponding 
VAS line to represent the answers to each question. Answers 
ranged from "Not at all" at 0 to "All the time" at 100 mm. 
Severity of nausea, for example, as measured on the VAS, was 
defined as the following: 0 = no nausea; 1-30 mm = mild nau- 
sea; 31-70 mm = moderate nausea; 71-100 mm = severe nausea. 
A pharmacist collected the patients' daily self-assessment 
cards and asked subjects about their condition over the past 
24 hours. Nursing services recorded the daily number of 
episodes of emesis (expulsion of stomach contents). Retch- 
ing, defined as visceral contraction without expulsion of 
stomach contents, was tallied as an emetic episode. The 
number of emetic episodes was confirmed with the patient 
each day. The investigators monitored and recorded adverse 
effects and determined whether the effects were related to 
the study medications. 
Response to antiemetic therapy was defined as the follow- 
ing: complete response, the complete absence of emesis and 
mild-to-moderate nausea; major response, 1 or 2 episodes of 
emesis on only 1 day with any level of nausea or no emesis 
with severe nausea; minor response, 1or 2 episodes of emesis 
on more than 1 day with any level of nausea; and treatment 
failure, more than 2 episodes of emesis on any 1 day of the 
conditioning regimen or 2 emetic episodes on at least 3 days 
of the conditioning regimen. Emesis occurring within 2 hours 
of infusing stem cells containing dimethyl sulfoxide (DMSO) 
was not considered an antiemetic failure .... 
The choice of rescue medication was left to provider 
discretion; however, the agent, dose, and route were charted 
on the medication administration record and tracked by 
indication and quantity. I f  needed for patient comfort or 
safety, rescue medication was administered on a regularly 
scheduled basis at investigator discretion. 
Stat i s t i cs  
With 30 patients in each arm and a baseline response 
rate of 0.78 on standard therapy, it can be concluded that the 
true difference is not less than 0.27 assuming the response 
rate in the dolasetron arm is also 0.78. If the response rate in 
the dolasetron arm is 0.85 or greater, it can be concluded 
that the true difference between treatment arms was no more 
than 0.18. These calculations assume a large sample test 
based on the normal distribution for testing in the 2 propor- 
tions. The error levels of 0~ for this study are set at 0.05 for 
2-tailed tests, and the 13 error for this study is set at 0.2. 
Chi-square tests were used to examine nominal data, 
and 2-tailed t tests were used to compare the means of con- 
tinuous data. The Mann-Whimey U or Wilcoxon rank-sum 
test for difference in medians was used to compare data that 
were not normally distributed. All statistical analyses were 
performed on NCSS 2000 statistical software. 
RESULTS 
Sixty-three patients were screened and randomized into 
1 of the 2 treatment arms. One patient in the standard ther- 
apy treatment group was then excluded after having experi- 
enced a medication error, leaving 31 patients in each treatment 
arm. Demographic data are shown in Table 2. There were 
no significant differences between the 2 groups. Similar con- 
ditioning regimens were employed between the 2 groups. 
Because 3 of the first 5 patients treated in the dolasetron 
group did not experience more than 1 emetic episode per 
day for more than 2 days, all subjects in the experimental 
treatment arm received single daily doses of dolasetron as 
outlined previously. 
Safety  
No instances of cardiac or unexpected rug-related 
adverse ffects were reported in either treatment group. 
I n tent ion  to  T reat  
The total numbers of  days of  condit ioning therapy 
among the dolasetron-treated patients and standard ther- 
apy-treated patients were 188 days and 179 days, respectively. 
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Table 3. Number of Days Without Retching," or Vomiting 
Days of Retch/Vomit-Free 
Conditioning, n Days, n 
Intention-to-treat 
Dolasetron 188 144 
Standard 179 159 
p <.005 
Conditioning therapy-matched 
Dolasetron 124 90 
Standard 124 109 
P <.005 
Dolasetron-treated patients were free from emetic episodes 
on 144 days of conditioning, and the standard therapy- 
treated patients had 159 conditioning days free of emesis 
(P < .005) (Table 3). The total number of emetic episodes 
on each day of treatment was also compared. A statistically 
significant difference was identified on day -1 (P < .001) 
(Figure I). 
Major or complete responses were achieved in 20 of the 
dolasetron-treated patients compared to 27 patients in the 
standard treatment group. The numbers of patients having 
a minor response or treatment failure were 11 patients in 
the dolasetron group and 4 patients in the standard group 
(P > .05) (Table 4). 
None of the mean VAS scores differed significantly 
between the 2 groups at baseline. A significant difference 
was observed between the 2 groups at day -4 for the first 
question, "Do you have nausea?" (Figure 2). Also, patients' 
perception of vomiting indicated that the dolasetron-treated 
group felt they were vomiting significantly more than did 
the standard therapy group on days -4, -2, and -1 (P < .05) 
(Figure 3). These data corroborate the number of emetic 
episodes recorded. There were no differences discovered 
between the 2 groups in the remaining questions. 
Cond i t ion ing  Therapy-Matched 
Forty-four patients (22 in each arm) were then matched 
by conditioning regimens post-hoc in an attempt to elimi- 
nate biases that may have occurred because of differing eme- 
togenicity between regimens. The maximum number of 
patients available to be matched were selected according to 
regimen, sex, age, and disease. The demographic data and 
baseline VAS scores were similar between the 2 groups. 
Patients in each group received 124 days of conditioning 
therapy. The dolasetron-treated group experienced 90 days 
free from retching or vomiting and the standard therapy 
group experienced 109 days without an emetic episode (P < 
.005). Response rates exhibited a similar pattern to that of 
the intent ion-to- t reat  group. "I~velve patients in the 
dolasetron group had a complete or major response, and 
19 patients in the standard therapy group achieved a com- 
plete or major response (P < .05). 
A difference was noted in the VAS question "Do you 
have nausea?" at day -4 and day -1 (Figure 2). A nonsignifi- 
cant trend favoring standard therapy was observed in the 
score of the question, "Do you vomit?" (Figure 3), and no 
differences were noted in the questions of taste changes. 
However, in contrast to the intention-to-treat group, there 
was a statistically significant difference for the question, 
"How much of an appetite do you have?" at days -6, -5, -4, 
and - t  that favored standard therapy (P < .05). 
Rescue Med icat ion  
The dolasetron arm required 377 doses of rescue 
antiemetics, whereas the standard therapy arm required 
306 doses. There appeared to be an increased use of oral 
thiethylperazine and lorazepam in the dolasetron group, 
whereas IV diphenhydramine and droperiol were used 
more in the standard therapy group. Use of other rescue 
antiemetics was negligible. There was no statistically signifi- 
cant difference between the 2 study groups in the mean 





Day -8 Day -7 Day -6 Day -5 Day -4 Day -3 Day -2 Day -1 
Day of conditioning therapy 
Figure I. Episodes of retching or emesis. 
--Eli-- Dolesetran 
-~-  Standard 
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Table 4. Number of Patients in Each Group VUbo Had a Complete or Major 
Response Versus aMinor Response orTreatment Failure 
Group~Type of Response Dolasetron, n Standard, n P 
Intention-to-treat 
Complete or major 20 27  <.05  
Minor or failure I I 4 
Conditioning therapy-matched 
Complete or major 12 19 <.05  
Minor or failure 10 3 
DISCUSSION 
The objective of this study was to compare the safety and 
efficacy of dolasetron with granisetron and ondansetron i
patients undergoing high-dose chemotherapy followed by 
HSCT. The results of this study suggest that dolasetron, at 
the dose studied, is less effective at reducing nausea nd eme- 
sis in patients undergoing HSCT than our institution's stan- 
dard granisetron- and ondansetron-containing regimens. 
These results challenge the assumption that the 5-HT 3 
receptor antagonists currently available for treatment and 
prevention of chemotherapy-induced nausea and vomiting 
are equivalent in efficacy when used in patients undergoing 
high-dose myeloablative chemotherapy followed by HSCT. 
Although no study has compared olasetron to either 
granisetron or ondansetron i  patients undergoing high-dose 
chemotherapy followed by HSCT, no studies have detected 
any appreciable differences between the 5-HT 3 receptor 
antagonists when used in comparable doses in other settings. 
The definition of response in this study differs from that in 
other trials performed in BMT patients. Previous trials exam- 
ining 5-HT 3 receptor antagonists used less stringent thresh- 
olds in determining treatment failures. For example, 
Okamoto et al. [15] defined minor control as 3 or 4 vomiting 
episodes and failure as 5 or more episodes in a 24 hour period 
in BMT patients when comparing a granisetron-treated 
group to an active control group. Abang et al. [16] used a 
threshold of greater than 3 episodes in 24 hours as treatment 
failure with no regard to nausea when comparing IV to oral 
granisetron i  patients undergoing peripheral blood pro- 
genitor cell transplantation a d BMT. Frakes et al. [17] also 
required more than 3 episodes in 24 hours, but looked at nau- 
sea as a separate ntity while examining ranisetron i BMT 
patients in a noncomparative trial. In our study, treatment 
failure was defined as more than 2 episodes of emesis on any 1 
day of the conditioning regimen or 2 emetic episodes on at 
least 3 days of the conditioning regimen. Additionally, we 
determined that a minor response was 1 or 2 episodes of eme- 
sis on more than 1 day with any level of nausea. These more 
stringent criteria may prove better suited to distinguish the 
subtle differences in efficacy between agents. If these previ- 
ous, less stringent criteria had been applied, few or no failures 
would have been seen [t 5-17]. 
Multiple regression analysis showed that no factor 
other than treatment group significantly correlated with 
response results. Patient demographics appeared to be sim- 
ilar at baseline in both the intention-to-treat group and the 
conditioning therapy matched subgroup. However, there 
tended to be more men in the standard treatment arm and 
more heavy drinkers (defined as daily use or binge drink- 
ing) in the intention-to-treat standard regimen group. 
Both of these factors are thought o decrease the risk of 
nausea and vomiting associated with chemotherapy, but 
they did not significantly influence the results in this 
analysis. There was a similar distribution of patients 
between conditioning regimens among both groups, so it 
is unlikely that 1 treatment arm was exposed to more 
marked emetogenic regimens. A subgroup analysis of 
patients matched to conditioning therapy regimens was 
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Day of conditioning therapy 
Figure 2. Median visual analogue scale (VAS) scores for the question, "Do you have nausea?" 
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Figure 3. Median visual analogue scale (VAS) scores for the question, "Do you vomit?" 
It is interesting to note that there was an increased fre- 
quency of severe (grade 3 or 4) mucositis posttransplantation 
in patients in the dolasetron group overall, but this was not 
statistically sign!ficant compared with the occurrence in the 
standard treatment group. Also, in correlating antiemetic 
response to severe mucositis, 7 patients were identified who 
had both a poor response to prophylaxis of nausea nd vomit- 
ing and severe mucositis, raising the question of whether 
increased retching leads to increased mucositis. All 7 of those 
patients were treated with myeloablative chemotherapy regi- 
mens containing both cyclophosphamide and TBI, and 
6 were in the dolasetron arm. The results een in this small 
sample raise the suspicion that inadequate prophylaxis against 
retching and vomiting may lead to increased mucositis. 
Although there were statistical differences between the 
groups in the median VAS results of the questions "Do you 
have nausea?" and "Do you vomit?" it is virtually impossible 
to assess the clinical relevance of such differences in subjective 
measurements. However, although it is difficult to assess the 
clinical difference between "mild nausea" and "moderate nau- 
sea" among patients, it is easier to assign clinical value to the 
objective difference between emesis and no emesis. The 
objective measurements of this study differed significantly 
between the treatment groups in statistical analysis and are 
clearly of value to clinical practice. This difference was evi- 
dent among patients matched for conditioning therapy as well 
as in the intention-to-treat group. Additionally, the condi- 
tioning therapy matched patients treated with dolasetron 
experienced a sig~aificant i crease in anorexia compared to the 
standard therapy patients. This finding suggests that decrease 
in control of nausea and emesis contributed to decreased 
appetite among these patients. Although no objective data 
such as caloric intakes were gathered, the clinical relevance of 
anorexia to the nutritional goals of cancer patients undergo- 
ing myeloablative r gimens can be appreciated. 
The dolasetron-treated group required more rescue 
medications, which correlated with clinically apparent nau- 
sea and vomiting. It is interesting to note that there was 
more use of IV rescue medication in the standard therapy 
arm. Because the route of administration was left to the dis- 
cretion of the care provider, it remains possible that patients 
who received IV rescue medications may have been per- 
ceived to have experienced more severe nausea s assessed 
by their providers. Dolasetron-treated patients were more 
likely to receive oral rescue antiemetics, uggesting that 
their nausea nd vomiting were perceived to be less severe. 
The difference in efficacy between the oral and IV rescue 
antiemetics used in this study may have influenced the num- 
ber of rescue doses given, as well as the overall control of 
nausea nd vomiting. Current guidelines ponsored by the 
American Society of Health-System Pharmacists (ASHP) 
suggest that for highly emetogenic chemotherapy, there is a 
benefit o increasing the dose of dolasetron to 200 mg per 
day [18]. It may be that an increased ose of dolasetron will 
make these 5-t-IT 3 receptor antagonists interchangeable, as 
suggested in our original hypothesis. 
Prior to the completion of this study, we assumed that 
all 5-HT 3 receptor antagonists had equivalent efficacy in 
prophylaxis of nausea nd vomiting in patients undergoing 
high-dose chemotherapy with HSCT. Using this assump- 
tion and the 1998 average wholesale price, a cost minimiza- 
tion comparison between the 5 -HT 3 antagonists in our 
standard antiemetic regimens and dolasetron indicated that 
dolasetron would be a potential cost-saving alternative. 
According to the analysis, dolasetron cost approximately 
$575.32 per round of high-dose chemotherapy with HSCT, 
whereas tandard therapy cost $829.87, on average. How- 
ever, because the cost of antiemetic therapy is dependent on 
the conditioning therapy, there are regimens uch as Cyl20- 
TBI1200 in which the cost of the standard antiemetic regimen 
was actually less expensive than the dolasetron-containing 
regimen. When examining costs across regimens, the aver- 
age cost of dolasetron prophylaxis (drug cost only) was 
approximately $724.82 per course of chemotherapy, whereas 
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the cost of the 5 -HT  3 receptor antagonist in the standard 
regimen cost $491.84 per round of chemotherapy in this 
study. Because we did not find these products to be equiva- 
lent, a cost minimization analysis could not be performed. If 
doubling the dose of dolasetron does provide equal efficacy, 
it is less likely to be a cost-minimizing alternative. However, 
it is important o note that the cost savings to institutions 
should be weighted according to their use in various condi- 
t ioning regimens. Rescue antiemetics were not accounted 
for in the analysis because their cost is negligible in compar- 
ison to that of the 5 -HT  3 receptor antagonists. However, it 
is important to acknowledge the significant amount of nurs- 
ing resources required to administer these rescue agents, 
especially via the IV route. 
CONCLUSION 
Th is  study demonstrated that at the doses studied, 
dolasetron is a less effective alternative than other 5 -HT  3 
receptor antagonists used in our standard antiemetic regi- 
mens for the prevention of nausea and vomiting in patients 
undergoing high-dose chemotherapy followed by HSCT.  
Dolasetron was less effective, and it does not appear that 
dolasetron can be considered as a more cost-effective alter- 
native in all patients undergoing high-dose chemotherapy 
and HSCT. 
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